¡GoConqr estrena diseño! Cuéntanos qué te parece.

Regístrate gratis

Test

MD30 Systemic availability

Mer Scott 12 preguntas

Hacer el test

Este test tiene tipos de pregunta que se abren en el reproductor de siempre.

Preguntas del test (12)

  1. 1Bioavailability — historic term: “A measure of the [blank_start]rate and extent[blank_end] of drug absorption, that quantifies the [blank_start]amount[blank_end] of drug that reaches the [blank_start]systemic[blank_end] circulation”. By referring to drug absorption, it implies that we can ignore [blank_start]first pass metabolism[blank_end], which we can't.
    Systemic availability "F" — "The [blank_start]fraction[blank_end] of a dose that reaches the systemic circulation." Applicable to [blank_start]any[blank_end] administration route but ignores [blank_start]rate[blank_end].
    1. Arate and extent
    2. Bamount
    3. Csystemic
    4. Dfirst pass metabolism
    5. Efraction
    6. Fany
    7. Grate
  2. 2Parameters for the [blank_start]extent[blank_end] of drug absorption:
    [blank_start]Cmax[blank_end] - Maximum observed concentration
    [blank_start]AUC[blank_end] - Area under the concentration-time curve

    Parameters for the [blank_start]rate[blank_end] of drug absorption:
    [blank_start]Tmax[blank_end] - Time that the maximum concentration (Cmax) is observed
    [blank_start]Ka[blank_end] - Absorption rate constant
    1. Aextent
    2. BCmax
    3. CAUC
    4. Drate
    5. ETmax
    6. FKa
  3. 3Absolute bioavailability (F) is the ratio of the AUC in the [blank_start]systemic circulation[blank_end] after oral ingestion, and the AUC from [blank_start]intravenous dosing[blank_end]. Oral bioavailability is [blank_start]less[blank_end] due to first pass metabolism.
    To calculate the dose that reaches the systemic circulation from an oral dose we multiply the [blank_start]oral dose[blank_end] by [blank_start]F[blank_end].
    In theory, you might need to give a [blank_start]bigger[blank_end] oral dose to achieve the same drug exposure (AUC) as [blank_start]intravenous[blank_end] dosing.

    1. Asystemic circulation
    2. Bintravenous dosing
    3. Cless
    4. Doral dose
    5. EF
    6. Fbigger
    7. Gintravenous
  4. 4Relative bioavailability refers to a case where the intravenous dose is [blank_start]not the comparator[blank_end].
    Requirements for a comparison of AUC’s:
    1. Same [blank_start]drug and dose[blank_end]
    2. [blank_start]Clearance[blank_end] must not change between the comparators
    3. Linear pharmacokinetics (AUC is [blank_start]proportional[blank_end] to dose)
    4. No other factors alter drug [blank_start]bioavailability[blank_end] (food, drug interactions)
    1. Anot the comparator
    2. Bdrug and dose
    3. CClearance
    4. Dproportional
    5. Ebioavailability
  5. 5There are three primary determinants of bioavailability;
    1. [blank_start]Disintegration and dissolution[blank_end] of the drug
    2. [blank_start]Absorption[blank_end] across the membranes in the gut wall
    3. Pre-systemic [blank_start]metabolism[blank_end] (or ‘first-pass’) and [blank_start]elimination[blank_end]
    1. ADisintegration and dissolution
    2. BAbsorption
    3. Cmetabolism
    4. Delimination
  6. 6Choose the correct equation.
    1. AF = fa / fh
    2. BF = fa x fh
    3. CF = fh / fa
  7. 7Mechanisms for first pass elimination:
    1. Metabolism in the [blank_start]gut wall[blank_end] (e.g. oestrogens, atorvastatin)
    2. [blank_start]Efflux[blank_end] from the gut wall (e.g. dabigatran)
    3. [blank_start]Esterase[blank_end] metabolism in the plasma of the [blank_start]portal circulation[blank_end] (e.g. aspirin)
    4. Metabolism in the [blank_start]liver[blank_end] (most common)
    1. Agut wall
    2. BEfflux
    3. CEsterase
    4. Dportal circulation
    5. Eliver
  8. 8Pre-systemic drug interactions impact peak plasma concentration (Cmax) not clearance.
    1. AVerdadero
    2. BFalso
  9. 9P-gps are responsible for gut wall efflux.
    1. AVerdadero
    2. BFalso
  10. 10High E by the liver means low fh.
    1. AVerdadero
    2. BFalso

Información

Descripción
(Medicines) PHCY211 Test sobre MD30 Systemic availability, creado por Mer Scott el 27/05/2018.
Idioma
English
Visitas
7
Valoración
Aún sin valoraciones
Valora este test
Valora este test

Escríbenos

¿Sobre qué es tu mensaje?

¿Qué te parece el nuevo diseño?

¿Te gusta?